{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:32:58Z","timestamp":1788460378587,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Zuranolone, the latest oral medication for postpartum depression, was approved in the United States in August 2023. Due to its pharmacokinetic characteristics and rapid onset of action, it is hailed as a breakthrough and enhanced version of the drug. However, there is limited information on adverse drug reactions associated with its use. The primary objective of this study is to assess the post-marketing safety of Zuranolone. This study utilizes the FAERS database to analyze the safety of Zuranolone and provide a reference for clinical safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data on Zuranolone were collected from the FAERS database, covering the period from the third quarter of 2023 to the second quarter of 2024. Disproportionate analysis was used to quantify adverse drug reaction signals associated with Zuranolone and to detect risk signals from the data in the FAERS database. The Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Convolutional Probabilistic Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS) were used collectively to detect risk signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This study identified 154 reports primarily suspecting Zuranolone and 426 adverse drug events from a total of 1,626,204 adverse event (AE) reports. A total of 142 Preferred Terms (PTs) were identified across 18 System Organ Classes (SOCs). Most reports originated from the United States, with various health professionals and consumers being the main reporters. Adverse reactions following Zuranolone administration predominantly involved Nervous system disorders and Psychiatric disorders. Specific adverse reactions included Somnolence, Dizziness, Fatigue, Sedation, Suicidal ideation, Tremor, Feeling abnormal, Headache, Anxiety, and Nausea. The onset of AEs related to Zuranolone was not prolonged (average onset time of 4 days, with a median onset time of 2 days). Compared to Brexanolone, Zuranolone\u2019s adverse reactions were more focused on nervous system diseases, while the latter was primarily associated with psychiatric disorders, General disorders and administration site conditions, and Injury, poisoning and procedural complications. Some adverse reactions related to Zuranolone were reported frequently but were not documented in the prescribing information, including Insomnia, Vertigo, Vision blurred, Migraine, and Muscle twitching.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study revealed potential AEs of Zuranolone, confirming known safety information about Zuranolone, providing comprehensive data for medical practice and public health decision-making, and laying the foundation for further clinical research. It also provides more comprehensive and updated evidence for the clinical safety of Zuranolone.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1517773","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:28:11Z","timestamp":1755235691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Post marketing safety assessment of the novel postpartum depression drug, Zuranolone: evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system"],"prefix":"10.3389","volume":"16","author":[{"given":"Duoqin","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoying","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1146\/annurev-clinpsy-050212-185612","article-title":"Postpartum depression: current status and future directions","volume":"9","author":"O\u2019Hara","year":"2013","journal-title":"Annu Rev Clin Psychol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-041217-011106","article-title":"Postpartum depression: pathophysiology, treatment, and emerging therapeutics","volume":"70","author":"Stewart","year":"2019","journal-title":"Annu Rev Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.16121","article-title":"Prevalence and risk factors of postpartum depression in women: A systematic review and meta-analysis","volume":"31","author":"Liu","year":"2022","journal-title":"J Clin Nurs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2020.05.001","article-title":"Postpartum depression: identification and treatment in the clinic setting","volume":"47","author":"Kroska","year":"2020","journal-title":"Obstet Gynecol Clin North Am"},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00737-023-01378-1","article-title":"Post marketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)","volume":"27","author":"Zhang","year":"2024","journal-title":"Arch Womens Ment Health"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00605-7","article-title":"Pharmacotherapy of postpartum depression: current approaches and novel drug development","volume":"33","author":"Frieder","year":"2019","journal-title":"CNS Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020979627","article-title":"Brexanolone: A novel drug for the treatment of postpartum depression","volume":"35","author":"Patatanian","year":"2022","journal-title":"J Pharm Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.03.057","article-title":"Different dosage regimens of zuranolone in the treatment of major depressive disorder: A meta-analysis of randomized controlled trials","volume":"354","author":"Lian","year":"2024","journal-title":"J Affect Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2334160","article-title":"Indirect comparisons of relative efficacy estimates of zuranolone and selective serotonin reuptake inhibitors for postpartum depression","volume":"27","author":"Meltzer-Brody","year":"2024","journal-title":"J Med Econ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1080\/13696998.2024.2327946","article-title":"The cost-effectiveness of zuranolone versus selective serotonin reuptake inhibitors for the treatment of postpartum depression in the United States","volume":"27","author":"O\u2019Callaghan","year":"2024","journal-title":"J Med Econ"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1425295","article-title":"Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis","volume":"15","author":"Raja","year":"2024","journal-title":"Front Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01953-x","article-title":"Zuranolone: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"Eclinicalmedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2024.06.005","article-title":"Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system","volume":"90","author":"Zhang","year":"2024","journal-title":"Gen Hosp Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: A review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01404-w","article-title":"Detection algorithms for simple two-group comparisons using spontaneous reporting systems","volume":"47","author":"Noguchi","year":"2024","journal-title":"Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115450","article-title":"The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials","volume":"328","author":"Zou","year":"2023","journal-title":"Psychiatry Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.01.268","article-title":"The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials","volume":"351","author":"Clayton","year":"2024","journal-title":"J Affect Disord"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis","year":"2023","journal-title":"Am J Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/NDT.S466260","article-title":"Clinical utility of zuranolone for postpartum depression: A narrative review","volume":"21","author":"Giannopoulos","year":"2025","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2025.110317","article-title":"Effect of two novel GABAA receptor positive allosteric modulators on neuropathic and inflammatory pain in mice","volume":"269","author":"Xu","year":"2025","journal-title":"Neuropharmacology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2021.1559","article-title":"Effect of zuranolone vs placebo in postpartum depression: A randomized clinical trial","volume":"78","author":"Deligiannidis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2023.11.009","article-title":"Vestibular compensation: Neural mechanisms and clinical implications for the treatment of vertigo","volume":"51","author":"Takeda","year":"2024","journal-title":"Auris Nasus Larynx"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/00016489850154883","article-title":"Effects of the neurosteroid dehydroepiandrosterone sulfate on medial vestibular nucleus neurons","volume":"118","author":"Yamamoto","year":"1998","journal-title":"Acta Otolaryngol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.13201\/j.issn.2096-7993.2024.03.015","article-title":"Research advances in the mechanism of vestibular compensation and treatment","volume":"38","author":"Li","year":"2024","journal-title":"Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/00016489609137820","article-title":"Receptor pharmacological models for the therapy of labyrinthine vertigo","volume":"116","author":"Ehrenberger","year":"1996","journal-title":"Acta Otolaryngol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01561-3","article-title":"Translocator protein (18kDa) TSPO: a new diagnostic or therapeutic target for stress-related disorders","volume":"27","author":"Rupprecht","year":"2022","journal-title":"Mol Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2021.1961503","article-title":"Neuroinflammation and psychiatric disorders: Relevance of C1q, translocator protein (18 kDa) (TSPO), and neurosteroids","volume":"23","author":"Rupprecht","year":"2022","journal-title":"World J Biol Psychiatry"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2014.0186","article-title":"Extrasynaptic release of GABA and dopamine by retinal dopaminergic neurons","volume":"370","author":"Hirasawa","year":"2015","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.exer.2013.02.017","article-title":"The effects and interactions of GABAergic and dopaminergic agents in the prevention of form deprivation myopia by brief periods of normal vision","volume":"110","author":"Schmid","year":"2013","journal-title":"Exp Eye Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.18071\/isz.77.0227","article-title":"An update on approved and emerging drugs for the treatment of postpartum depression","volume":"77","author":"Culcu","year":"2024","journal-title":"Ideggyogy Sz"},{"key":"B33","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","journal-title":"Sci Rep"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1517773\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:28:12Z","timestamp":1755235692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1517773\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":33,"alternative-id":["10.3389\/fpsyt.2025.1517773"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1517773","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1517773"}}